Literature DB >> 27983728

Safety and acceptability of an organic light-emitting diode sleep mask as a potential therapy for retinal disease.

J N Sahni1,2, G Czanner2,3, T Gutu1, S A Taylor1, K M Bennett4, S M Wuerger4, I Grierson2, C Murray-Dunning2, M N Holland5, S P Harding1,2.   

Abstract

PurposeThe purpose of the study was to study the effect of an organic light-emitting diode sleep mask on daytime alertness, wellbeing, and retinal structure/function in healthy volunteers and in diabetic macular oedema (DMO).Patients and methodsHealthy volunteers in two groups, 18-30 yrs (A), 50-70 yrs (B) and people with DMO (C) wore masks (504 nm wavelength; 80 cd/m2 luminance; ≤8 h) nightly for 3 months followed by a 1-month recovery period. Changes from baseline were measured for (means): psychomotor vigilance task (PVT) (number of lapses (NL), response time (RT)), sleep, depression, psychological wellbeing (PW), visual acuity, contrast sensitivity, colour, electrophysiology, microperimetry, and retinal thickness on OCT.ResultsOf 60 participants, 16 (27%) withdrew, 8 (13%) before month 1, due to sleep disturbances and mask intolerance. About 36/55 (65%) who continued beyond month 1 reported ≥1 adverse event. At month 3 mean PVT worsened in Group A (RT (7.65%, P<0.001), NL (43.3%, P=0.005)) and mean PW worsened in all groups (A 28.0%, P=0.01, B 21.2%, P=0.03, C 12.8%, P<0.05). No other clinically significant safety signal was detected. Cysts reduced/resolved in the OCT subfield of maximal pathology in 67% Group C eyes. Thinning was greater at 3 and 4 months for greater baseline thickness (central subfield P<0.001, maximal P<0.05).ConclusionSleep masks showed no major safety signal apart from a small impairment of daytime alertness and a moderate effect on wellbeing. Masks were acceptable apart from in some healthy participants. Preliminary data suggest a beneficial effect on retinal thickness in DMO. This novel therapeutic approach is ready for large clinical trials.

Entities:  

Mesh:

Year:  2016        PMID: 27983728      PMCID: PMC5233944          DOI: 10.1038/eye.2016.259

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  23 in total

1.  Subjective and objective sleepiness in the active individual.

Authors:  T Akerstedt; M Gillberg
Journal:  Int J Neurosci       Date:  1990-05       Impact factor: 2.292

2.  Examination of short binary sequences for mfERG recording.

Authors:  Richard P Hagan; Anthony C Fisher; Malcolm C Brown
Journal:  Doc Ophthalmol       Date:  2006-08-30       Impact factor: 2.379

3.  Transmission of light across the adult and neonatal eyelid in vivo.

Authors:  J Robinson; S C Bayliss; A R Fielder
Journal:  Vision Res       Date:  1991       Impact factor: 1.886

4.  Exposure to room light before bedtime suppresses melatonin onset and shortens melatonin duration in humans.

Authors:  Joshua J Gooley; Kyle Chamberlain; Kurt A Smith; Sat Bir S Khalsa; Shantha M W Rajaratnam; Eliza Van Reen; Jamie M Zeitzer; Charles A Czeisler; Steven W Lockley
Journal:  J Clin Endocrinol Metab       Date:  2010-12-30       Impact factor: 5.958

5.  Validation of the Karolinska sleepiness scale against performance and EEG variables.

Authors:  Kosuke Kaida; Masaya Takahashi; Torbjörn Akerstedt; Akinori Nakata; Yasumasa Otsuka; Takashi Haratani; Kenji Fukasawa
Journal:  Clin Neurophysiol       Date:  2006-05-06       Impact factor: 3.708

6.  Regression of early diabetic macular oedema is associated with prevention of dark adaptation.

Authors:  G B Arden; S Jyothi; C H Hogg; Y F Lee; S Sivaprasad
Journal:  Eye (Lond)       Date:  2011-10-21       Impact factor: 3.775

7.  The validity of two versions of the GHQ in the WHO study of mental illness in general health care.

Authors:  D P Goldberg; R Gater; N Sartorius; T B Ustun; M Piccinelli; O Gureje; C Rutter
Journal:  Psychol Med       Date:  1997-01       Impact factor: 7.723

8.  A preliminary trial to determine whether prevention of dark adaptation affects the course of early diabetic retinopathy.

Authors:  G B Arden; M K Gündüz; A Kurtenbach; M Völker; E Zrenner; S B Gündüz; U Kamis; B T Oztürk; S Okudan
Journal:  Eye (Lond)       Date:  2010-02-05       Impact factor: 3.775

Review 9.  Magnitude of cognitive dysfunction in adults with type 2 diabetes: a meta-analysis of six cognitive domains and the most frequently reported neuropsychological tests within domains.

Authors:  Priya Palta; Andrea L C Schneider; Geert Jan Biessels; Pegah Touradji; Felicia Hill-Briggs
Journal:  J Int Neuropsychol Soc       Date:  2014-02-20       Impact factor: 2.892

10.  Age, performance and sleep deprivation.

Authors:  Pierre Philip; Jacques Taillard; Patricia Sagaspe; Cédric Valtat; Montserrat Sanchez-Ortuno; Nicholas Moore; André Charles; Bernard Bioulac
Journal:  J Sleep Res       Date:  2004-06       Impact factor: 3.981

View more
  2 in total

1.  Clinical efficacy and safety of a light mask for prevention of dark adaptation in treating and preventing progression of early diabetic macular oedema at 24 months (CLEOPATRA): a multicentre, phase 3, randomised controlled trial.

Authors:  Sobha Sivaprasad; Joana C Vasconcelos; A Toby Prevost; Helen Holmes; Philip Hykin; Sheena George; Caroline Murphy; Joanna Kelly; Geoffrey B Arden
Journal:  Lancet Diabetes Endocrinol       Date:  2018-03-05       Impact factor: 32.069

2.  A Real-World Single-Centre Study of Patients with Diabetic Macular Oedema Who Wore a Home-Use Sleep Mask (Noctura 400) for One Year.

Authors:  Ulrich Meyer-Bothling; Oliver Meyer-Bothling; Marika Pinney
Journal:  J Ophthalmol       Date:  2021-06-15       Impact factor: 1.909

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.